JP2022533358A - 終末糖化産物受容体ｒｎａのモジュレーター及び調節 - Google Patents

終末糖化産物受容体ｒｎａのモジュレーター及び調節 Download PDF

Info

Publication number
JP2022533358A
JP2022533358A JP2021568406A JP2021568406A JP2022533358A JP 2022533358 A JP2022533358 A JP 2022533358A JP 2021568406 A JP2021568406 A JP 2021568406A JP 2021568406 A JP2021568406 A JP 2021568406A JP 2022533358 A JP2022533358 A JP 2022533358A
Authority
JP
Japan
Prior art keywords
rage
aons
aon
exon
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021568406A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533358A5 (enExample
Inventor
ウィルトン，スティーブン
クリストファー トーマス，マーリン
ロサド，カルロス
ジェーン ピッカリング，レリーン
Original Assignee
モナシュ ユニバーシティ
マードック ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019901641A external-priority patent/AU2019901641A0/en
Application filed by モナシュ ユニバーシティ, マードック ユニバーシティ filed Critical モナシュ ユニバーシティ
Publication of JP2022533358A publication Critical patent/JP2022533358A/ja
Publication of JP2022533358A5 publication Critical patent/JP2022533358A5/ja
Priority to JP2025061149A priority Critical patent/JP2025106369A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021568406A 2019-05-14 2020-05-07 終末糖化産物受容体ｒｎａのモジュレーター及び調節 Pending JP2022533358A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025061149A JP2025106369A (ja) 2019-05-14 2025-04-02 終末糖化産物受容体ｒｎａのモジュレーター及び調節

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
AU2019901641 2019-05-14
AU2019901641A AU2019901641A0 (en) 2019-05-14 Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA
AU2019902095A AU2019902095A0 (en) 2019-06-17 Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA
AU2019902095 2019-06-17
AU2019902772A AU2019902772A0 (en) 2019-08-02 Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA
AU2019902772 2019-08-02
AU2019903900 2019-10-16
AU2019903900A AU2019903900A0 (en) 2019-10-16 Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA
PCT/AU2020/050449 WO2020227758A1 (en) 2019-05-14 2020-05-07 Modulators and modulation of the receptor for advanced glycation end-products rna

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025061149A Division JP2025106369A (ja) 2019-05-14 2025-04-02 終末糖化産物受容体ｒｎａのモジュレーター及び調節

Publications (2)

Publication Number Publication Date
JP2022533358A true JP2022533358A (ja) 2022-07-22
JP2022533358A5 JP2022533358A5 (enExample) 2023-08-15

Family

ID=73290056

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568406A Pending JP2022533358A (ja) 2019-05-14 2020-05-07 終末糖化産物受容体ｒｎａのモジュレーター及び調節
JP2025061149A Pending JP2025106369A (ja) 2019-05-14 2025-04-02 終末糖化産物受容体ｒｎａのモジュレーター及び調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025061149A Pending JP2025106369A (ja) 2019-05-14 2025-04-02 終末糖化産物受容体ｒｎａのモジュレーター及び調節

Country Status (12)

Country Link
US (3) US11441148B2 (enExample)
EP (1) EP3969590A4 (enExample)
JP (2) JP2022533358A (enExample)
KR (1) KR20220009971A (enExample)
CN (1) CN114127288A (enExample)
AU (2) AU2020276337B2 (enExample)
BR (1) BR112021022714A2 (enExample)
CA (1) CA3140209A1 (enExample)
IL (1) IL288040A (enExample)
MX (1) MX2021013858A (enExample)
SG (1) SG11202112144RA (enExample)
WO (1) WO2020227758A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220009971A (ko) 2019-05-14 2022-01-25 모나쉬 유니버시티 최종당화산물 수용체 알엔에이의 조절인자 및 조절
JP2026516053A (ja) * 2023-05-05 2026-05-19 レイジ バイオテック ピーティワイ エルティーディー オリゴヌクレオチドの投与
AU2023447004A1 (en) * 2023-05-05 2025-10-16 RAGE Biotech Pty Ltd Methods of monitoring splicing
KR20260027924A (ko) * 2023-05-19 2026-03-03 레이지 바이오텍 피티와이 리미티드 연기 노출의 영향 최소화 방법
JP2026518714A (ja) * 2023-05-19 2026-06-09 レイジ バイオテック ピーティワイ エルティーディー 肺線維症を治療する方法
EP4768586A1 (en) * 2023-09-27 2026-07-01 Changchun Genescience Pharmaceutical Co., Ltd. NEW ARNSI, COMPOSITION, INCLUDING IT AND USE
AU2024359647A1 (en) * 2023-10-12 2026-03-12 RAGE Biotech Pty Ltd Rnai agents targeting rage
WO2025222258A1 (en) * 2024-04-24 2025-10-30 RAGE Biotech Pty Ltd Methods of treating or preventing obstructive pulmonary disease
WO2025236048A1 (en) * 2024-05-17 2025-11-20 RAGE Biotech Pty Ltd Methods of treating the effects of smoke

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003125786A (ja) * 2001-03-19 2003-05-07 Univ Kanazawa 可溶型ｒａｇｅタンパク質

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US20020123476A1 (en) 1991-03-19 2002-09-05 Emanuele R. Martin Therapeutic delivery compositions and methods of use thereof
US6806084B1 (en) 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
WO1997022371A1 (en) 1995-12-18 1997-06-26 Collagen Corporation Crosslinked polymer compositions and methods for their use
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
AU3243300A (en) 1999-02-23 2000-09-14 Isis Pharmaceuticals, Inc. Multiparticulate formulation
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7026121B1 (en) * 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
AU2006242371A1 (en) * 2005-04-29 2006-11-09 The University Of North Carolina At Chapel Hill Methods and compositions for regulated expression of nucleic acid at post-transcriptional level
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
JP2010233542A (ja) * 2009-03-31 2010-10-21 Kanazawa Univ Ｒａｇｅ遺伝子の２種類のスプライシングバリアントを区別して増幅可能なプライマーセット及びプローブ
US20100303776A1 (en) * 2009-04-16 2010-12-02 The University Of North Carolina At Chapel Hill Methods and compositions for regulated expression of multiple nucleic acids
WO2013027104A1 (en) 2011-08-25 2013-02-28 Db Equipment As Accessory bag having reinforced sidewalls and variable length
US20210246454A1 (en) * 2018-05-17 2021-08-12 Lifesplice Pharma Llc Splice modulating oligonucleotides targeting receptor for advanced glycation end products and methods of use
KR20220009971A (ko) 2019-05-14 2022-01-25 모나쉬 유니버시티 최종당화산물 수용체 알엔에이의 조절인자 및 조절

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003125786A (ja) * 2001-03-19 2003-05-07 Univ Kanazawa 可溶型ｒａｇｅタンパク質

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A.AARTSMA-RUS, ET AL., RNA, vol. 13, JPN6024015268, 2007, pages 1609 - 1624, ISSN: 0005653445 *
A.Z.KALEA, ET AL., FRONTIERS IN BIOSCIENCE, vol. 16, JPN6024015229, 2011, pages 2756 - 2770, ISSN: 0005653444 *

Also Published As

Publication number Publication date
WO2020227758A1 (en) 2020-11-19
WO2020227758A8 (en) 2021-11-18
US20230015481A1 (en) 2023-01-19
US12565656B2 (en) 2026-03-03
JP2025106369A (ja) 2025-07-15
CN114127288A (zh) 2022-03-01
US20240141360A1 (en) 2024-05-02
BR112021022714A2 (pt) 2022-01-18
KR20220009971A (ko) 2022-01-25
US20210388363A1 (en) 2021-12-16
CA3140209A1 (en) 2020-11-19
EP3969590A1 (en) 2022-03-23
MX2021013858A (es) 2022-03-22
SG11202112144RA (en) 2021-11-29
US11674143B2 (en) 2023-06-13
AU2020276337B2 (en) 2025-05-29
AU2025223886A1 (en) 2025-09-18
US11441148B2 (en) 2022-09-13
AU2020276337A1 (en) 2021-12-02
EP3969590A4 (en) 2024-05-15
IL288040A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
US11674143B2 (en) Modulators and modulation of the receptor for advanced glycation end-products RNA
CN105838714B (zh) 反义分子和治疗疾病的方法
US20230407309A1 (en) Antisense oligomers for treatment of disease
US20250066782A1 (en) Novel Retinitis Pigmentosa Treatment
CA3193706A1 (en) Treatment of optic atrophy
RU2820247C2 (ru) Модуляторы и модуляция рнк рецептора конечных продуктов глубокого гликирования
CN113383076B (zh) 用于ptp1b相关病症的反义疗法
HK40069896A (en) Modulators and modulation of the receptor for advanced glycation end-products rna
WO2021042161A1 (en) Antisense oligonucleotide therapy for cancer
US20250368988A1 (en) Compositions and Methods for Treating FUS Associated Diseases
CA3149735C (en) Antisense oligonucleotide therapy for cancer
US20250340873A1 (en) Method for Treating Cyclophilin D Associated Diseases
US20250270548A1 (en) Compositions and methods for treating tardbp associated diseases
JP2018515110A (ja) 多発性硬化症の治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230804

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240913

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250501